Where does GlaxoSmithKline LLC rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), GlaxoSmithKline LLC ranks #3,119 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does GlaxoSmithKline LLC hold?

GlaxoSmithKline LLC holds 121 US utility patents granted between 2015 and 2025, spanning 45 technology areas.

What is GlaxoSmithKline LLC's Innovation Score?

GlaxoSmithKline LLC has an Innovation Score of 49.0 out of 100 (top 15% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does GlaxoSmithKline LLC focus on?

GlaxoSmithKline LLC's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 78 patents, ranking #217 of 6,058 assignees active in that subclass. Grants appear in 45 CPC subclasses total.

Is GlaxoSmithKline LLC's patent grant rate increasing or decreasing?

GlaxoSmithKline LLC's recent grant velocity is -92% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for GlaxoSmithKline LLC's patents?

GlaxoSmithKline LLC's patents average 11.1 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the GlaxoSmithKline LLC patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

GlaxoSmithKline LLC

USPTO PatentsView assignee record - 121 granted patents across 45 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Glaxosmithkline ranks #3,119 of 49,997 tracked US assignees by granted-patent volume, with 121 patents across 45 technology areas.

#3,119
of 49,997 US assignees by volume: Top 15%
by Innovation Score (49.0/100): 11.1
avg claims per patent: -92%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R3119 · US Corporation #3,119 · 121 grants

GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-WIDE · INNOV-PAR · CLAIMS-PAR · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-MID 121 grants
TOP-DECILE #3,119/49,997
PHOTO-FINISH Faraday Technology
CPC-WIDE A61P · 45 areas
INNOV-PAR 49.0/100
CLAIMS-PAR 11.1 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -92% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Faraday Technology Corp. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Glaxosmithkline’s 49.0 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 16.6 pts (34%) Velocity 2.1 pts (4%) Breadth 23.7 pts (48%) Claim depth 6.7 pts (14%)

Qualcomm Incorporated · highest

85
GlaxoSmithKline · this assignee

49
Immunogen · near

49
Manicka Institute · near

49
Thales Alenia Space… · near

49
Smartsky Networks · near

49
3D Lighting… · lowest

7

What this shows Glaxosmithkline's Innovation Score is 49.0/100 (top 15% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Glaxosmithkline?

Each dot is one of Glaxosmithkline’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Glaxosmithkline’s own 11.1 claims/patent is at or below the 13.8 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Glaxosmithkline vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Glaxosmithkline's grants concentrate

GlaxoSmithKline LLC is a focused PatentsView assignee: 45 CPC subclasses with 64.5% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2015 (34 grants) versus a trough of 1 in 2021. By volume, Glaxosmithkline sits between Fuji Machine MFG. Co., Ltd. and Purac Biochem BV.

Glaxosmithkline's three-year grant acceleration

GlaxoSmithKline LLC shows 5 grants in 2022–2024 against only 16 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Fuji Machine MFG

121
Faraday Technology

121
Ferring B V

121
Georgia-pacific C…

121
Hefei BOE Display…

121
Institute of Auto…

121
Landscape Forms

121
Purac Biochem BV

121
Glaxosmithkline ◀

121

What this shows GlaxoSmithKline holds 121 patents at rank #3,119, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near GlaxoSmithKline

By rank, the assignees closest to #3,119 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in GlaxoSmithKline's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for GlaxoSmithKline, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), GlaxoSmithKline ranks #217 of 6,058 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (49 here).

Immunogen, Inc. 49 Thales Alenia Space Italia S.p.A. Con Unico Socio 49 Manicka Institute LLC 49 Smartsky Networks LLC 49

Similar claim depth

Nearest assignees by average claims per patent (11.1 here).

Nippon Steel Chemical & Material Co., Ltd. 11.1 avg Samsonite IP Holdings S.a r.l. 11.1 avg Ishihara Sangyo Kaisha, Ltd. 11.1 avg Virtual Hold Technology Solutions, LLC 11.1 avg

Glaxosmithkline's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

49 Top 15% higher than 85% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

GlaxoSmithKline LLC patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	34	28.1%
2016	17	14.0%
2017	27	22.3%
2018	21	17.4%
2019	12	9.9%
2020	3	2.5%
2021	1	0.8%
2022	2	1.7%
2023	1	0.8%
2024	2	1.7%
2025partial year	1	0.8%

Which technologies does GlaxoSmithKline LLC patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 78

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 72

C07D - Heterocyclic Compounds 70

C07K - Peptides 9

Y02A - Technologies FOR Adaptation TO Climate Change 9

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 7

C07C - Acyclic OR Carbocyclic Compounds 5

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 5

B05D - Processes FOR Applying Fluent Materials TO Surfaces, IN General 5

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 4

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 4

C07J - Steroids 4

B05B - Spraying APPARATUS; Atomising APPARATUS; Nozzles 4

A61J - Containers Specially Adapted FOR Medical OR Pharmaceutical PURPOSES; Devices OR Methods Specially Adapted FOR Bringing Pharmaceutical Products Into Particular Physical OR Administering FORMS; Devices FOR Administering Food OR Medicines ORALLY; Baby COMFORTERS; Devices FOR Receiving Spittle 3

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 2

Top 15 of 45 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

GlaxoSmithKline LLC's patent record in context - here's where to go next.

GlaxoSmithKline LLC's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 64.5% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #3,119 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare GlaxoSmithKline LLC against Fuji Machine MFG. Co., Ltd., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 49.0/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.